ALEMTUZUMAB FOR RELAPSING AND REFRACTORY PRIMARY SYSTEMIC VASCULITIS - A TRIAL OF EFFICACY AND SAFETY (ALEVIATE): A RANDOMISED OPEN-LABEL PHASE II CLINICAL TRIAL

被引：0
|
作者：
Gopaluni, Seerapani [1 ]
Goymer, Donna [2 ]
McClure, Mark [1 ]
Cahill, Hugh [2 ]
Broadhurst, Elizabeth [2 ]
Smith, Rona [1 ]
Jayne, David [1 ]
机构：
[1] Univ Cambridge, Cambridge, England
[2] Cambridge Univ Hosp NHS Trust, Cambridge, England
来源：
RHEUMATOLOGY | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
302
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
    Seerapani Gopaluni
    Rona Smith
    Donna Goymer
    Hugh Cahill
    Elizabeth Broadhurst
    Elizabeth Wallin
    Mark McClure
    Afzal Chaudhry
    David Jayne
    Arthritis Research & Therapy, 24
  • [2] Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
    Gopaluni, Seerapani
    Smith, Rona
    Goymer, Donna
    Cahill, Hugh
    Broadhurst, Elizabeth
    Wallin, Elizabeth
    McClure, Mark
    Chaudhry, Afzal
    Jayne, David
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [3] Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
    Khanna, Dinesh
    Denton, Christopher P.
    Lin, Celia J. F.
    van Laar, Jacob M.
    Frech, Tracy M.
    Anderson, Marina E.
    Baron, Murray
    Chung, Lorinda
    Fierlbeck, Gerhard
    Lakshminarayanan, Santhanam
    Allanore, Yannick
    Pope, Janet E.
    Riemekasten, Gabriela
    Steen, Virginia
    Mueller-Ladner, Ulf
    Spotswood, Helen
    Burke, Laura
    Siegel, Jeffrey
    Jahreis, Angelika
    Furst, Daniel E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 212 - 220
  • [4] ALEMTUZUMAB FOR THE TREATMENT OF REFRACTORY BEHCET'S DISEASE: A SUBGROUP ANALYSIS FROM A RANDOMIZED, PROSPECTIVE, OPEN LABEL, DOSE RANGING CLINICAL TRIAL (NCT01405807). A TRIAL OF EFFICACY AND SAFETY (ALEVIATE)
    Prasinou, Maria
    Smith, Rona
    Gopaluni, Seerapani
    Jayne, David
    RHEUMATOLOGY, 2019, 58 : 150 - 150
  • [5] Efficacy of RestoreX after prostatectomy: open-label phase of a randomised controlled trial
    Chung, Eric
    BJU INTERNATIONAL, 2023, 132 (05) : 465 - 466
  • [6] 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis:: A six-month open-label trial to evaluate safety and efficacy
    Birck, R
    Warnatz, K
    Lorenz, HM
    Choi, M
    Haubitz, M
    Grünke, M
    Peter, HH
    Kalden, JR
    Göbel, U
    Drexler, JM
    Hotta, O
    Nowack, R
    Van der Woude, FJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02): : 440 - 447
  • [7] Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
    Zhang, Chao
    Zhang, Meini
    Qiu, Wei
    Ma, Hongshan
    Zhang, Xinghu
    Zhu, Zilong
    Yang, Chun-Sheng
    Jia, Dongmei
    Zhang, Tian-Xiang
    Yuan, Meng
    Feng, Yan
    Yang, Li
    Lu, Wenli
    Yu, Chunshui
    Bennett, Jeffrey L.
    Shi, Fu-Dong
    LANCET NEUROLOGY, 2020, 19 (05) : 391 - 401
  • [8] Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial
    Rastvorceva, Rada M. Grubovic
    Useini, Sedula
    Stevanovic, Milena
    Demiri, Ilir
    Petkovic, Elena
    Franchini, Massimo
    Focosi, Daniele
    LIFE-BASEL, 2022, 12 (10):
  • [9] Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
    Khanna, Dinesh
    Lin, Celia J. F.
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [10] Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
    Alkhouri, Naim
    Herring, Robert
    Kabler, Heidi
    Kayali, Zeid
    Hassanein, Tarek
    Kohli, Anita
    Huss, Ryan S.
    Zhu, Yanni
    Billin, Andrew N.
    Damgaard, Lars Holm
    Buchholtz, Kristine
    Kjaer, Mette Skalshoi
    Balendran, Clare
    Myers, Robert P.
    Loomba, Rohit
    Noureddin, Mazen
    JOURNAL OF HEPATOLOGY, 2022, 77 (03) : 607 - 618
12345